I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

Angiogenesis 2025

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Feb 9 / Roche and Genentech
Faricimab▼ in DME: Results From the RHONE-X Long-Term Extension Trial
This presentation reports findings from the RHONE-X extension trial, which evaluated the long-term safety and efficacy of faricimab▼ in patients with DME who completed either of the 2-year randomized phase 3 clinical trials (YOSEMITE/RHINE). This is the largest DME extension study to date with over 1400 patients enrolled. We also present a case study of a patient who followed for 4 years and was treated with aflibercept in YOSEMITE and switched to faricimab▼ in RHONE-X.

Sign up or login to unlock the full suite of MEDICALLY features

Feb 9 / Roche and Genentech
Faricimab▼ for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial
This presentation describes the week 16 (interim) results of the phase 3b/4 SALWEEN study. SALWEEN is investigating the efficacy, safety and durability of faricimab▼ in patients with polypoidal choroidal vasculopathy (PCV) from Asian countries/regions. Interim efficacy and safety results have demonstrated robust improvements in vision and anatomy, and complete closure and inactivation of polypoidal lesions in the majority of patients. Faricimab▼ was well tolerated and consistent with the known safety profile of faricimab▼.

Sign up or login to unlock the full suite of MEDICALLY features

Feb 9 / Roche and Genentech
First Time Analysis of Fellow Eyes with DME in the Pagoda Port Delivery System Study
In this post-hoc analysis of the Pagoda study, patients randomized to the PDS arm and having bilateral DME are evaluated. PDS Q24W in the study eye demonstrates greater CST and DRSS control, similar vision and safety outcomes with aVEGF IVT treatment in the fellow eye through week 112, with reduced treatment burden.
08:35 PM
Duration 8mins Virtual
Faricimab▼ for Polypoidal Choroidal Vasculopathy: Week 16 Results From the Phase 3b/4 SALWEEN Trial
Cheung G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:45 PM
Duration 8mins Virtual
Faricimab▼ in DME: Results From the RHONE-X Long-Term Extension Trial
John A Wells III

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:55 PM
Duration 8mins Virtual
Treatment Response and Safety of Faricimab▼ in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US
Veeral Sheth

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:55 PM
Duration 8mins Virtual
First Time Analysis of Fellow Eyes with DME in the Pagoda Port Delivery System Study
Eichenbaum D, Graff J, Hsieh Y, Hsu, J, Udaondo P, Wirthlin R, Blotner S, Gune S, Jones M, Santhanakrishan A, Schimpl A, Heinrich D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar